ACST vs. UBX, FBRX, NRXP, SNSE, ITRM, LPCN, BFRG, APRE, BIOR, and LUMO
Should you be buying Acasti Pharma stock or one of its competitors? The main competitors of Acasti Pharma include Unity Biotechnology (UBX), Forte Biosciences (FBRX), NRx Pharmaceuticals (NRXP), Sensei Biotherapeutics (SNSE), Iterum Therapeutics (ITRM), Lipocine (LPCN), Bullfrog AI (BFRG), Aprea Therapeutics (APRE), Biora Therapeutics (BIOR), and Lumos Pharma (LUMO). These companies are all part of the "pharmaceutical preparations" industry.
Acasti Pharma (NASDAQ:ACST) and Unity Biotechnology (NASDAQ:UBX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, community ranking, risk, earnings, media sentiment, institutional ownership and dividends.
In the previous week, Acasti Pharma had 2 more articles in the media than Unity Biotechnology. MarketBeat recorded 2 mentions for Acasti Pharma and 0 mentions for Unity Biotechnology. Acasti Pharma's average media sentiment score of 0.00 equaled Unity Biotechnology'saverage media sentiment score.
Acasti Pharma's return on equity of -13.18% beat Unity Biotechnology's return on equity.
Acasti Pharma has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500. Comparatively, Unity Biotechnology has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500.
Acasti Pharma received 139 more outperform votes than Unity Biotechnology when rated by MarketBeat users. Likewise, 70.52% of users gave Acasti Pharma an outperform vote while only 66.15% of users gave Unity Biotechnology an outperform vote.
Unity Biotechnology has higher revenue and earnings than Acasti Pharma. Acasti Pharma is trading at a lower price-to-earnings ratio than Unity Biotechnology, indicating that it is currently the more affordable of the two stocks.
6.1% of Acasti Pharma shares are owned by institutional investors. Comparatively, 29.5% of Unity Biotechnology shares are owned by institutional investors. 13.5% of Acasti Pharma shares are owned by company insiders. Comparatively, 4.9% of Unity Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Acasti Pharma currently has a consensus target price of $6.00, suggesting a potential upside of 103.39%. Unity Biotechnology has a consensus target price of $6.00, suggesting a potential upside of 275.00%. Given Unity Biotechnology's higher possible upside, analysts clearly believe Unity Biotechnology is more favorable than Acasti Pharma.
Summary
Acasti Pharma and Unity Biotechnology tied by winning 7 of the 14 factors compared between the two stocks.
Get Acasti Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACST and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Acasti Pharma Competitors List
Related Companies and Tools
